ESTRELLA IMMUNOPHARMA, INC.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2021 | $-819 | $-819 | — | — |
| Jun 2021 | $-6.1K | $-6.1K | — | — |
| Sep 2021 | $-16.0K | $-16.0K | — | — |
| Dec 2021 | $-293.3K | $-293.3K | — | — |
| Mar 2022 | $-157.1K | $-157.1K | — | — |
| Jun 2022 | $-233.4K | $-233.4K | — | — |
| Sep 2022 | $-1.1M | $-1.1M | — | $102.4K |
| Dec 2022 | $-108.2K | $-108.2K | — | $102.4K |
| Mar 2023 | $-275.7K | $-275.7K | — | $102.4K |
| Jun 2023 | $-212.7K | $-212.7K | — | $102.4K |
| Sep 2023 | $-275.2K | $-275.2K | — | $1.2M |
| Dec 2023 | $-11.3M | $-11.3M | — | $0 |
| Mar 2024 | $-4.2M | $-4.2M | — | $0 |
| Jun 2024 | $-291.5K | $-291.5K | — | $0 |
| Sep 2024 | $-2.2M | $-2.2M | — | — |
| Dec 2024 | $-896.1K | $-896.1K | — | — |
| Mar 2025 | $-466.0K | $-466.0K | — | $159.1K |
| Jun 2025 | $-414.9K | $-414.9K | — | $159.1K |
| Sep 2025 | $-727.3K | $-727.3K | — | $152.4K |
| Dec 2025 | $-177.5K | $-177.5K | — | $148.4K |
| Mar 2026 | $-6.7M | $-6.7M | — | $146.7K |
| Jun 2026 | $-1.8M | $-1.8M | — | $145.3K |